登录 | 注册    关注公众号  
微信公众号
搜索
 > 【HLA-C】

HLA-C产品咨询

* 此表格只用于收集产品需求咨询,所有信息将严格保密。
*
*
*
*
*
*
抗体药
 
细胞治疗
 
基因治疗
 
诊断
 
疫苗
 
化药
 
蛋白及多肽药物
 
神经科学
 
XDC
 
其他
 
ACRO质量管理体系
 
评论(0)
 

HLA-C 分子别名

HLA-C

HLA-C 分子背景

HLA-A, B, and C are transmembrane glycoproteins in the major histocompatibility complex 1 (MHC I) family. The C receptor is a heterodimer consisting of a HLA-C mature gene product (heavy chain) and β2-microglobulin (light chain). The mature C chain is anchored in the membrane. HLA class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. HLA-C are expressed in nearly all cells, and present small peptides to the immune system which surveys for non-self peptides.

HLA-C 前沿进展

Identification of a Novel HLA-C*15:292 Allele by Next-Generation Sequencing
Keweier, Guo, Qiao et al
HLA (2025) 105 (4), e70122
Abstract: HLA-C*15:292 differs from HLA-C*15:02:01 by a G>A substitution in exon 2.© 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma
Zhang, Yu, Guo et al
Cancer Immunol Immunother (2025) 74 (5), 158
Abstract: Malignant mesothelioma is a highly aggressive cancer with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME) plays a pivotal role in driving tumor progression, with immune cells influencing disease outcomes. However, the molecular mechanisms underpinning mesothelioma's progression remain insufficiently understood. HLA-C, a class I major histocompatibility complex (MHC) molecule, has been implicated in immune modulation and cancer progression, but its specific role in mesothelioma has yet to be thoroughly investigated.This study employed a comprehensive multi-omics approach, integrating single-cell RNA sequencing, expression quantitative trait loci (eQTL) analysis, and Mendelian randomization (MR), to elucidate the role of HLA-C in mesothelioma progression. We first analyzed HLA-C expression within the TME, with particular focus on immune cells, especially macrophages. Survival analysis was conducted using data from the TCGA mesothelioma cohort to assess the clinical relevance of HLA-C expression. We utilized mediated MR analysis to investigate the impact of DNA methylation on HLA-C expression, identifying key mediators such as inflammatory cytokines, immune cell populations, blood cell types, and metabolites that could potentially influence patient prognosis.HLA-C was predominantly expressed in macrophages, T cells, and NK cells within the TME, and higher expression levels were associated with improved patient survival. MR analysis revealed that DNA methylation regulates HLA-C expression, which in turn impacts mesothelioma outcomes. Mediated MR analysis, encompassing 91 inflammatory cytokines, 731 immune cell populations, 91 blood cell types, and 1400 metabolites, highlighted several critical mediators of HLA-C's effect on prognosis, including IL-10, CD33 expression on CD33dim HLA DR- myeloid cells, the reticulocyte perturbation response, and the ADP-to-citrate ratio. Gene set enrichment analysis (GSEA) showed significant enrichment of immune-related and inflammatory pathways in patients with high HLA-C expression.HLA-C, regulated by DNA methylation, plays a central role in mesothelioma prognosis by modulating immune responses, inflammatory cytokines, blood cell populations, and metabolic processes within the TME. Our findings suggest that HLA-C could serve as both a prognostic biomarker and a potential therapeutic target for mesothelioma, offering new insights into the molecular mechanisms driving this aggressive cancer.© 2025. The Author(s).
Characterisation of the Novel HLA-C*04:534 Allele by Sequencing-Based Typing
Blandin, Cargou, Guidicelli et al
HLA (2025) 105 (3), e70147
Abstract: HLA-C*04:534 differs from HLA-C*04:01:01:01 by two nucleotide substitutions in codons 166 and 167 in exon 3.© 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Showing 1-3 of 4745 papers.
Powered by BizGenius

消息提示

请输入您的联系方式,再点击提交!

确定